Igenomix is a medical testing laboratory specializing in reproductive genetic services.
Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.

In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services for IVF clinics, founded in 2011. Together we create Vitrolife Group, a global leader in reproductive health. By combining Igenomix’s portfolio of reproductive genetic testing services with Vitrolife’s best-in-class IVF device portfolio, we support clinics and patients across the fertility journey.

Based on science and advanced research capabilities, our aim is to deliver products and services for the entire fertility journey, providing consistent performance and guaranteed quality. We are a sustainable market leader and aim to be the preferred partner to the fertility clinics by providing superior products and services. Currently, Vitrolife Group are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 110 countries, through our own presence in 32 countries, and a network of distributors.
Our vision is to enable people to fulfill the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients.  Together we create excellence in reproductive health.

The Vitrolife AB (publ) share is listed on Nasdaq Stockholm.

Fertility

Health Care

Life Sciences

Medical Devices

Igenomix

Igenomix's headquarters in Paterna, Spain

��

Description

People (1)

Jobs (0)

Other offices

��������

Description

People (1)

Jobs (0)

Other offices

��